Plain-English translation of NCT06641089 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called , given as a subcutaneous injection (under the skin), to see if it can help people with psoriatic arthritis — a condition that causes joint pain, swelling, and skin problems — who haven't had good results with other biologic treatments. Researchers will compare at two different doses against a placebo (inactive injection) and another existing medication to see which works best.
Many people with psoriatic arthritis don't get adequate relief from standard biologic treatments, leaving them with ongoing pain and disability. This trial investigates whether this new treatment can help these patients achieve better control of their symptoms.
You likely qualify if…
You likely don't qualify if…
If you're selected, you'll be randomly assigned to receive one of four treatments: at one dose, at a second dose, placebo, or the comparison medication . You'll start with an initial phase of four injections given over several weeks, then continue with maintenance injections every 4 weeks. Throughout the study, you'll visit the clinic regularly so doctors can monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States